Guardant Health has an expanding pipeline that could significantly boost its future market potential. Check out my ...

As reproductive health access becomes increasingly restricted across the country, expanding Washington’s law that protects ...

CMS approves ADLT status for Guardant Health's Shield test, setting Medicare reimbursement at $1,495. The analyst sees a ...

Guardant Health said the CMS determination confirms that the Shield test meets the criteria for ADLT status, which is reserved for innovative products that provide novel clinical information that ...

Guardant Health ( NASDAQ: GH) traded higher in the morning hours on Tuesday after the company announced that the U.S. Centers ...

Guardant Health (GH) announced the Centers for Medicare & Medicaid Services CMS has approved Advanced Diagnostic Laboratory Test ADLT ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Centers for Medicare & Medicaid ...

There is a new and less invasive option to test for colon cancer and it doesn’t require a stay at the hospital or mailing a stool sample.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a collaboration with Dak Prescott’s ...

​Guardant Health has filed a lawsuit against its competitor, Natera, alleging the misappropriation of trade secrets related to cancer-detection blood tests, according to court documents.